Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
9/9/26 Tyra Biosciences (TYRA) TYRA-300 for Bladder Cancer Subscribers Only Subscribers Only Subscribers Only
9/8/26 Structure (GPCR) aleniglipron for Obesity Subscribers Only Subscribers Only Subscribers Only
9/8/26 Bristol Myers Squibb (BMY) Arlo-cel for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
9/2/26 Teva Pharmaceutical Industries (TEVA) TEV-53408 for Celiac Disease Subscribers Only Subscribers Only Subscribers Only
9/2/26 Jiangsu Hengrui Pharmaceuticals (600276:SS) SHR-1918 for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
09/30/2025 Subscribers Only Subscribers Only Trial Announcement - Trial Completion
10/28/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/31/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/13/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update